Copyright © Inderes 2011 - present. All rights reserved.
Log ind for at modtage meddelelser.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Selskabsmeddelelse

GENT: Gentian Diagnostics and Beckman Coulter Partner to Launch Gentian GCAL® Calprotectin Immunoassay

10.03.2025, 12.44
Gentian Diagnostics
Moss,10 March 2025

Gentian Diagnostics is pleased to announce the launch of the GCAL® Calprotectin
Immunoassay with Beckman Coulter Diagnostics to its clinical chemistry
platforms. This collaboration illustrates our commitment to enhance diagnostic
efficiency for improved treatment decisions.

The Gentian GCAL® Calprotectin Immunoassay enables precise measurement of
calprotectin in human plasma and serum. Circulating calprotectin is widely
recognized as a sensitive biomarker for detection and assessment of inflammation
across a broad range of diseases. This makes it a valuable tool in numerous
inflammatory and rheumatic diseases as well as in detection and risk assessment
of the inflammatory response in infections, highlighting its broad utility in
clinical practice.

"We are pleased to officially announce that Beckman Coulter Diagnostics, a
leader in the field of clinical diagnostics, is launching our GCAL® assay," says
Matti Heinonen, CEO of Gentian Diagnostics. "This partnership builds on our
long-standing relationship with Beckman Coulter and marks a significant
milestone in our commitment to advancing market development for circulating
calprotectin. By combining our innovative GCAL® assay with Beckman Coulter's
industry expertise and reach, we are poised to empower healthcare professionals
with more accurate and timely diagnostic tools, enhancing patient care and
outcomes."

About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Gentian's expertise and focus lies within homogenous
immunoassays, specifically infections, inflammations, kidney failures and
congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analyzers, the
company contributes to saving costs and protecting life. Gentian is
headquartered in Moss, Norway, serving the global human and veterinary
diagnostics markets through sales and representative offices in Sweden, USA, and
China. For more information, please visit www.gentian.com.

IR Contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Privatlivspræferencer

Inderes bruger cookies for at give en bedre brugeroplevelse og en personlig service. Ved at give samtykke til brugen af cookies kan vi udvikle en endnu bedre service og vil kunne levere indhold, der er interessant for dig.